| Hazard Information | Back Directory | [Uses]
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis[1]. | [in vivo]
Lutikizumab (0.0001-1 mg/kg, i.p., once) shows effective inhibition to the IL-6 production induced by IL-1α and IL-1β[1]. | Animal Model: | Female C57/BL6 mice with IL-1α and IL-1β injection[1] | | Dosage: | 0.0001-1 mg/kg | | Administration: | Intraperitoneal injection, 0.0001-1 mg/kg, once | | Result: | Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1α and IL-1β. |
| [References]
[1] Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015;7(3):605-19. DOI:10.1080/19420862.2015.1026501 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|